Correction to: 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association.
DOI: https://doi.org/10.1161/STR.0000000000000383
IF: 10.17
2021-06-30
Stroke
Abstract:1. On page e365, left column, the fifth paragraph read, 9. Several studies have evaluated secondary stroke prevention of patent foramen ovale closure since the previous guideline in 2014. It is now considered reasonable to close patent foramen ovale percutaneously in selected patients: those with younger age with nonlacunar stroke or no other cause at any age. It has been updated to read, 9. There have been several studies evaluating secondary stroke prevention of patent foramen ovale closure since the previous guideline in 2014. It is now considered reasonable to percutaneously close patent foramen ovale in patients who meet each of the following criteria: age 18 to 60 years, nonlacunar stroke, no other identified cause, and high risk patent foramen ovale features. 2. On page e374, Figure 2 has been substantively edited as follows: Second row, the green box, "ECG and basic laboratory tests* (Class 1)" has been moved down 1 layer to row 3. Fifth row, the orange box read, "Evaluate for cardiac SOE with TTE or TEE (Class 2b)." The box has been moved up 1 layer to the fourth row; the text has been updated to read, "Echocardiography to evaluate for cardiac SOE (Class 2a)"; and the color of the box changed to yellow in line with the Class of Recommendation change from Class 2b to Class 2a. Fifth row, the green box, the text read, "Non-invasive carotid imaging [CTA, MRA, or US] (Class 1)." It has been updated to read, "Non-invasive cervical carotid imaging [CTA, MRA, or US] (Class 1)." Fifth row, the second yellow box, the text read, "Non-invasive imaging of the intracranial arteries and the extracranial vertebrobasilar arterial system (Class 2a)." It has been updated to read, "Non-invasive intracranial and extracranial imaging of vertebrobasilar arterial system (Class 2a)." Sixth row, the green box, the text read, "Prolonged ECG (Class 1)" It has been updated to read, "Long-term cardiac rhythm monitoring (Class 2a)," and the box color has been changed to yellow in line with the Class of Recommendation change from Class 1 to Class 2a. Sixth row, the second orange box, "PFO screen‡ (Class 2b)" has been removed. Sixth row, the third orange box (now the second box) read, "Test for genetic stroke syndrome (Class 2b)." It has been updated to read, "Test for genetic stroke syndrome (Class 2a)," and the box color has been changed to yellow in line with the Class of Recommendation change from Class 2b to Class 2a. Sixth row, the fourth orange box (now the third box) read, "Test for vasculitis (Class 2b)." It has been updated to read, "Test for infectious vasculitis (Class 2a)," and the box color has been changed to yellow in line with the Class of Recommendation change from Class 2b to Class 2a. Sixth row, an orange box has been added to become the fourth box with the text, "TEE, Cardiac CT, or Cardiac MRI (Class 2b)." Sixth row, the fifth box read, "Evaluate for other rare causes of stroke (Class 2b)." it has been updated to read, "Evaluate for other rare causes of stroke," and the color has been removed in line with removal of the text "(Class 2b)." The revised figure is included below. 3. On page e386, right column, second paragraph, the first sentence read, "1. The REDUCE-IT trial (Reduction of Cardiovascular Events With Icosapent Ethyl–Insstervention Trial) 219 ...." It has been updated to read, "1. The REDUCE-IT trial (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial) 219 ...." Download figure Download PowerPoint These corrections have been made to the current online version of the article, which is available at https://www.ahajournals.org/doi/10.1161/STR.0000000000000375 .
peripheral vascular disease,clinical neurology